Scott McMeekin1, Don Dizon2, James Barter3, Giovanni Scambia4, Lyudmila Manzyuk5, Alla Lisyanskaya6, Ana Oaknin7, Sarah Ringuette8, Pralay Mukhopadhyay8, Julie Rosenberg9, Ignace Vergote10. 1. Stephenson Cancer Center, University of Oklahoma, Oklahoma City, OK, USA. Electronic address: scott-mcmeekin@ouhsc.edu. 2. Medical Gynecologic Oncology, Gillette Center for Women's Cancers, Massachusetts General Hospital, Boston, MA, USA. 3. Women's Health Specialists, Rockville, MD, USA. 4. Policlinico Universitario A. Gemelli, Rome, Italy. 5. Russian Oncology Research Center Named After Blokhin N.N., Moscow, Russia. 6. City Clinical Oncology Dispensary, St Petersburg, Russia. 7. Vall D'Hebron University Hospital, Barcelona, Spain. 8. Bristol-Myers Squibb, Wallingford, CT, USA. 9. Bayer HealthCare, Montville, NJ, USA. 10. University Hospital Leuven, Leuven Cancer Institute, Department of Oncology, KU Leuven, Belgium.
Abstract
OBJECTIVE: The purpose of this multicenter, open label, randomized phase III study was to determine whether ixabepilone resulted in improved overall survival (OS) compared with commonly used single-agent chemotherapy (doxorubicin or paclitaxel) in women with locally advanced, recurrent, or metastatic endometrial cancer with at least one failed prior platinum-based chemotherapeutic regimen. METHODS: Patients were randomized 1:1 to ixabepilone (40mg/m(2)), or either paclitaxel (175mg/m(2)) or doxorubicin (60mg/m(2)), every 21days. Patients that had previously received ananthracycline were randomized to ixabepilone or paclitaxel; all other patients were randomized to ixabepilone or doxorubicin. An interim analysis of futility for OS was planned. RESULTS: At the time of database lock, 496 patients were randomized to receive ixabepilone (n=248) or control (n=248); nine patients in the control arm were not treated. The interim analysis of futility for OS (219 events) favored the control chemotherapy arm (hazard ratio=1.3 [95% confidence interval: 1.0-1.7], stratified log rank test P=0.0397), indicating that the study would not meet its primary objective. The study was discontinued based on the interim OS results. The frequency of adverse events was comparable between the treatment arms. CONCLUSIONS: The study did not meet its primary objective of improving OS in the ixabepilone arm compared to the control chemotherapy arm. A favorable risk/benefit ratio was not observed for ixabepilone versus control at the time of the interim analysis. The safety results were consistent with the known safety profiles of ixabepilone and control.
RCT Entities:
OBJECTIVE: The purpose of this multicenter, open label, randomized phase III study was to determine whether ixabepilone resulted in improved overall survival (OS) compared with commonly used single-agent chemotherapy (doxorubicin or paclitaxel) in women with locally advanced, recurrent, or metastatic endometrial cancer with at least one failed prior platinum-based chemotherapeutic regimen. METHODS:Patients were randomized 1:1 to ixabepilone (40mg/m(2)), or either paclitaxel (175mg/m(2)) or doxorubicin (60mg/m(2)), every 21days. Patients that had previously received an anthracycline were randomized to ixabepilone or paclitaxel; all other patients were randomized to ixabepilone or doxorubicin. An interim analysis of futility for OS was planned. RESULTS: At the time of database lock, 496 patients were randomized to receive ixabepilone (n=248) or control (n=248); nine patients in the control arm were not treated. The interim analysis of futility for OS (219 events) favored the control chemotherapy arm (hazard ratio=1.3 [95% confidence interval: 1.0-1.7], stratified log rank test P=0.0397), indicating that the study would not meet its primary objective. The study was discontinued based on the interim OS results. The frequency of adverse events was comparable between the treatment arms. CONCLUSIONS: The study did not meet its primary objective of improving OS in the ixabepilone arm compared to the control chemotherapy arm. A favorable risk/benefit ratio was not observed for ixabepilone versus control at the time of the interim analysis. The safety results were consistent with the known safety profiles of ixabepilone and control.
Authors: Carol Aghajanian; Virginia Filiaci; Don S Dizon; Jay W Carlson; Matthew A Powell; Angeles Alvarez Secord; Krishnansu S Tewari; David P Bender; David M O'Malley; Ashley Stuckey; JianJiong Gao; Fanny Dao; Robert A Soslow; Heather A Lankes; Kathleen Moore; Douglas A Levine Journal: Gynecol Oncol Date: 2018-05-24 Impact factor: 5.482
Authors: Neesha C Dhani; Hal W Hirte; Lisa Wang; Julia V Burnier; Angela Jain; Marcus O Butler; Stephen Welch; Gini F Fleming; Jean Hurteau; Koji Matsuo; Daniela Matei; Waldo Jimenez; Carolyn Johnston; Mihaela Cristea; Katia Tonkin; Prafull Ghatage; Stephanie Lheureux; Anjali Mehta; Judy Quintos; Qian Tan; Suzanne Kamel-Reid; Olga Ludkovski; Ming-Sound Tsao; John J Wright; Amit M Oza Journal: Clin Cancer Res Date: 2020-01-28 Impact factor: 12.531
Authors: Adam Carie; Bradford Sullivan; Tyler Ellis; J Edward Semple; Taylor Buley; Tara Lee Costich; Richard Crouse; Suzanne Bakewell; Kevin Sill Journal: J Drug Deliv Date: 2016-12-01
Authors: Laura M Divine; Mai R Nguyen; Eric Meller; Riva A Desai; Batool Arif; Erinn B Rankin; Katherine H Bligard; Cherise Meyerson; Ian S Hagemann; Maria Massad; Premal H Thaker; Andrea R Hagemann; Carolyn K McCourt; Matt A Powell; David G Mutch; Katherine C Fuh Journal: Oncotarget Date: 2016-11-22
Authors: Christoph Eilenberger; Mario Rothbauer; Florian Selinger; Anna Gerhartl; Christian Jordan; Michael Harasek; Barbara Schädl; Johannes Grillari; Julian Weghuber; Winfried Neuhaus; Seta Küpcü; Peter Ertl Journal: Adv Sci (Weinh) Date: 2021-03-24 Impact factor: 16.806
Authors: Stephanie Lheureux; Carolyn McCourt; B J Rimel; Linda Duska; Gini Fleming; Helen Mackay; David Mutch; Sarah M Temkin; Jean Lynn; Elise C Kohn Journal: Gynecol Oncol Date: 2018-02-22 Impact factor: 5.304
Authors: Vicky Makker; Angela K Green; Robert M Wenham; David Mutch; Brittany Davidson; David Scott Miller Journal: Gynecol Oncol Res Pract Date: 2017-12-02